Author

F. Vizeacoumar

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Freywald· 1 shared A. Kusalik· 1 shared B. Trost· 1 shared C. Gaunt· 1 shared C. H. Eskiw· 1 shared D. Borrowood· 1 shared E.-M. E. Uhlemann· 1 shared F. S. Vizeacoumar· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiochemistry

A. Freywald

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MEMO1 is a Metal Containing Regulator of Iron Homeostasis in Cancer Cells

N. Dolgova, E.-M. E. Uhlemann, M. T. Boniecki, F. S. Vizeacoumar, M. Ralle, M. Tonelli, S. A. Abbas, J. Patry, H. Elhasasna, A. Freywald, F. Vizeacoumar, O. Y. Dmitriev

This study identifies MEMO1 as an iron-binding protein that regulates iron homeostasis in cancer cells through interactions with iron-related proteins and its role in ferroptosis.

bioRxiv · Feb 28, 2023Biochemistry

Activation of the Anaphase Promoting Complex reverses multiple drug resistant cancer

T. Aranson, V. MacDonald-Dickinson, G. F. Davies, C. Gaunt, L. Lubanova, B. Trost, M. Waldner, P. Baldwin, D. Borrowood, H. Marwood, Z. E. Gillespie, F. Vizeacoumar, F. Vizeacoumar, C. H. Eskiw, A. Kusalik, T. A. A. Harkness

This study shows that activating the Anaphase Promoting Complex (APC) in dogs with multiple drug resistant lymphoma reduces MDR biomarkers and restores chemosensitivity, suggesting APC as a therapeutic target.

bioRxiv · May 26, 2020 · PreprintCancer Biology